Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows.
Alcohol use disorder
alcoholic cirrhosis
alcoholic liver disease
anti-craving drugs
liver transplantation
psychosocial approach
Journal
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
ISSN: 1878-7479
Titre abrégé: Neurotherapeutics
Pays: United States
ID NLM: 101290381
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
13
11
2019
medline:
5
2
2021
entrez:
13
11
2019
Statut:
ppublish
Résumé
Alcohol use disorder is the most common cause of advanced liver disease in the Western world. Diagnosis of alcohol use disorder can be difficult because patients with liver disease tend to deny alcohol intake for the fear of being excluded from treatment and because available biomarkers of alcohol intake have poor specificity in these patients. Alcohol abstinence is the cornerstone of the therapy in these patients. However, pharmacological treatments for alcohol use disorders have not been formally tested in patients with advanced liver disease, except for baclofen. Psychosocial intervention became crucial in these patients considering the limited pharmacological choice. However, psychosocial approach and an appropriate team to manage these patients are not still well defined. In this review, we critically discuss the diagnosis and the management of alcohol use disorder in patients with liver disease.
Identifiants
pubmed: 31713188
doi: 10.1007/s13311-019-00802-8
pii: 10.1007/s13311-019-00802-8
pmc: PMC7007485
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
127-141Références
Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009 Jun 27;373(9682):2223–33
doi: 10.1016/S0140-6736(09)60746-7
WHO. Global health risks—2011. Geneva, World Health Organization
WHO. Global Status Report on Alcohol and Health—2018. Geneva, World Health Organization
WHO. Global Status Report on Alcohol and Health—2014. Geneva, World Health Organization
Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007; 4(1):24–34
doi: 10.1038/ncpgasthep0683
Stein E, Cruz-Lemini M, Altamirano J, et al. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol. 2016; 65(5):998–1005
doi: 10.1016/j.jhep.2016.06.018
Dugum M, McCullough A. Diagnosis and Management of Alcoholic Liver Disease. J Clin Transl Hepatol. 2015; 3(2):109–16
doi: 10.14218/JCTH.2015.00008
pubmed: 4548353
pmcid: 4548353
Lucey MR. Liver transplantation for alcoholic liver disease. Nat Rev Gastroenterol Hepatol. 2014; 11(5):300–7
doi: 10.1038/nrgastro.2013.247
Goh ET, Morgan MY. Review article: pharmacotherapy for alcohol dependence—the why, the what and the wherefore. Aliment Pharmacol Ther. 2017; 45(7):865–82
Khan A, Tansel A, White DL, et al. Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2016; 14(2):191–202
doi: 10.1016/j.cgh.2015.07.047
Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016; 65(3):618–30
doi: 10.1016/j.jhep.2016.04.029
Hagman BT. Performance of the AUDIT in Detecting DSM-5 Alcohol Use Disorders in College Students. Subst Use Misuse. 2016; 51(11):1521–8
doi: 10.1080/10826084.2016.1188949
Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984; 252(14):1905–7
pubmed: 6471323
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption—II. Addiction. 1993; 88(6):791–804
doi: 10.1111/j.1360-0443.1993.tb02093.x
Connor JP, Haber PS, Hall WD. Alcohol use disorders. Lancet. 2016; 387(10022):988–98
doi: 10.1016/S0140-6736(15)00122-1
Maisto SA, Saitz R. Alcohol use disorders: screening and diagnosis. Am J Addict. 2003; 12(suppl 1):S12–25
doi: 10.1111/j.1521-0391.2003.tb00493.x
American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders, V Edition. American Psychiatry Association, 2013 Washington, DC, USA
Kummer N, Lambert WE, Samyn N, Stove CP. Alternative sampling strategies for the assessment of alcohol intake of living persons. Clin Biochem. 2016; 49(13–14):1078–91
doi: 10.1016/j.clinbiochem.2016.05.007
Berlakovich GA, Soliman T, Freundorfer E, et al. Pretransplant screening of sobriety with carbohydrate-deficient transferrin in patients suffering from alcoholic cirrhosis. Transpl Int. 2004; 17:617–21
doi: 10.1111/j.1432-2277.2004.tb00395.x
Allen JP, Wurst FM, Thon N, Litten RZ. Assessing the drinking status of liver transplant patients with alcoholic liver disease. Liver Transpl. 2013; 19:369–76
doi: 10.1002/lt.23596
Andresen-Streichert H, von Rothkirch G, Vettorazzi E, et al. Determination of Ethyl Glucuronide in Hair for Detection of Alcohol Consumption in Patients After Liver Transplantation. Ther Drug Monit. 2015; 37(4):539–45
doi: 10.1097/FTD.0000000000000160
Piano S, Marchioro L, Gola E, et al. Assessment of alcohol consumption in liver transplant candidates and recipients: the best combination of the tools available. Liver Transpl. 2014; 20(7):815–22
doi: 10.1002/lt.23881
Stewart SH, Koch DG, Willner IR, Anton RF, Reuben A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014; 38(6):1706–11
doi: 10.1111/acer.12442
pubmed: 4409698
pmcid: 4409698
Andresen-Streichert H, Beres Y, Weinmann W, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int. 2017; 30(6):611–620
doi: 10.1111/tri.12949
Barrio P, Wurst FM, Gual A. New Alcohol Biomarkers. New challenges. Alcohol Alcohol. 2018; 53(6):762–3
doi: 10.1093/alcalc/agy064
European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2018; 69:154–81
doi: 10.1016/j.jhep.2018.03.018
Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol. 2015; 12(4):231–42.
doi: 10.1038/nrgastro.2015.35
Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol. 2011; 8(9):491–501
doi: 10.1038/nrgastro.2011.134
Hart CL, Morrison DS , Batty GD et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010; 340:c1240
doi: 10.1136/bmj.c1240
pubmed: 2837144
pmcid: 2837144
Li S, Tan HY, Wang N, et al. The Role of Oxidative Stress and Antioxidants in Liver Diseases. Int J Mol Sci. 2015; 16:26087–124
doi: 10.3390/ijms161125942
pubmed: 4661801
pmcid: 4661801
Addolorato G, Ancona C, Capristo E, Gasbarrini G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int J Immunopathol Pharmacol. 2003; 16:207–14
doi: 10.1177/039463200301600304
Caballeria J, Parés A, Brù C, et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo control trial. Spanish group for the study of alcoholic fatty liver. J Hepatol. 1998; 28:54–60
doi: 10.1016/S0168-8278(98)80202-X
Bjørkhaug ST, Aanes H, Neupane SP, et al. Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption. Gut Microbes. 2019; 20:1–13
Vassallo G, Mirijello A, Ferrulli A, et al. Review article: Alcohol and gut microbiota—the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. Aliment Pharmacol Ther. 2015; 41(10):917–27
Posteraro B, Paroni Sterbini F, et al. Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats. Alcohol Clin Exp Res. 2018; 42(12):2313–25
doi: 10.1111/acer.13900
Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug; 75(2):193–9
doi: 10.1016/0016-5085(78)90401-8
Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005 Aug; 54(8):1174–9
doi: 10.1136/gut.2004.050781
pubmed: 1774903
pmcid: 1774903
Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol. 2012; 56 Suppl 1:S39–45
doi: 10.1016/S0168-8278(12)60005-1
Thursz MR, Richardson P, Allison M, et al; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015; 372(17):1619–28
doi: 10.1056/NEJMoa1412278
Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology. 2015; 149:958–70
doi: 10.1053/j.gastro.2015.06.006
Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011; 365:1781–89
doi: 10.1056/NEJMoa1101214
Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008; 48:465–70
doi: 10.1016/j.jhep.2007.10.010
Singal AK, Charlton MR. Nutrition in alcoholic liver disease. Clin Liver Dis. 2012; 16(4):805–26
doi: 10.1016/j.cld.2012.08.009
Rossi RE, Conte D, Massironi S. Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues. Dig Liver Dis. 2015; 47(10):819–25
doi: 10.1016/j.dld.2015.05.021
Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007; 6(5):442–55
doi: 10.1016/S1474-4422(07)70104-7
Mirijello A, D’Angelo C, Ferrulli A, et al. Identification and management of alcohol withdrawal syndrome. Drugs. 2015; 75(4):353–65
doi: 10.1007/s40265-015-0358-1
pubmed: 4978420
pmcid: 4978420
Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev. 2011; (6):CD008537
Leggio L, Lee MR. Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. Am J Med. 2017; 130(2):124–134
doi: 10.1016/j.amjmed.2016.10.004
American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014; 61(3):642–59
doi: 10.1016/j.jhep.2014.05.042
Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007; 370:1915–22
doi: 10.1016/S0140-6736(07)61814-5
Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med. 2006; 119(3):276.e13–8
doi: 10.1016/j.amjmed.2005.08.042
Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM. Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. J Hosp Med. 2011; 6:469–74
doi: 10.1002/jhm.928
Girish K, Reddy VK, Pandit LV, et al. A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Biomed J. 2016; 39(1):72–80
doi: 10.1016/j.bj.2015.09.002
pubmed: 6138810
pmcid: 6138810
Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev. 2015; 4:CD008502
Cooney G, Heydtmann M, Smith ID. Baclofen and the Alcohol Withdrawal Syndrome-A Short Review. Front. Psychiatry. 2019; 9:773
doi: 10.3389/fpsyt.2018.00773
pubmed: 6349735
pmcid: 6349735
Xie YD, Feng B, Gao Y, Wei L. Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systematic review and meta-analysis. Hepatol Res. 2014; 44:436–449
doi: 10.1111/hepr.12131
Addolorato G, Abenavoli L, Leggio L, Gasbarrini G. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology. 2005; 51(2):59–66
doi: 10.1159/000084161
Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis—a practical guide. Aliment Pharmacol Ther. 2013 Jun;37(12):1132–56
doi: 10.1111/apt.12324
Krampe H, Ehrenreich H. Supervised Disulfiram as Adjunct to Psychotherapy in Alcoholism Treatment. Curr Pharm Des. 2010; 16:2076–90
doi: 10.2174/138161210791516431
Skinner MD, Lahmek P, Pham H, et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014; 9:e87366
doi: 10.1371/journal.pone.0087366
pubmed: 3919718
pmcid: 3919718
European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012; 57(2):399–420
doi: 10.1016/j.jhep.2012.04.004
Litten RZ, Egli M, Heilig M, et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol. 2012; 17(3):513–27
doi: 10.1111/j.1369-1600.2012.00454.x
pubmed: 3484365
pmcid: 3484365
Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013; 108:275–93
doi: 10.1111/j.1360-0443.2012.04054.x
Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res. 2012; 36:318–24
doi: 10.1111/j.1530-0277.2011.01601.x
Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf. 2010; 9:177–88
doi: 10.1517/14740330903512943
Delgrange T, Khater J, Capron D, et al. Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis. Gastro-enterol Clin Biol. 1992; 16:687–91
Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013; 73(8):706–13
doi: 10.1016/j.biopsych.2012.10.020
Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23(11):1432–42
doi: 10.1016/j.euroneuro.2013.02.006
Van den Brink W, Sørensen P, Torup L, Mann K, Gual A; SENSE Study Group. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. J Psychopharmacol. 2014; 28(8):733–44
doi: 10.1177/0269881114527362
Skala K, Caputo F, Mirijello A, et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother. 2014; 15(2):245–57
doi: 10.1517/14656566.2014.863278
Mirijello A, Caputo F, Vassallo G, et al. GABAB Agonists for the Treatment of Alcohol Use Disorder. Curr Pharm Des. 2015; 21(23):3367–72
doi: 10.2174/1381612821666150619091858
Agence Nationale de Sécurité du Médicament et des Produits de Santé Avis de la commission mixte ad hoc sur l’évaluation de l’utilisation du baclofène dans le traitement des patients alcoolo-dépendants. https://ansm.sante.fr/content/download/146361/1931039/version/1/file/Avis-Commission-Baclofene-+4-juillet-05072018.pdf Date: 2018 Date accessed: October 23, 2018
Addolorato G, Caputo F, Capristo E, et al. Ability of baclofen in reducing alcohol craving and intake: II—Preliminary clinical evidence. Alcohol Clin Exp Res. 2000; 24(1):67–71
pubmed: 10656195
Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002; 37(5):504–8
doi: 10.1093/alcalc/37.5.504
Addolorato G, Leggio L, Ferrulli A, Baclofen Study Group, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011; 46(3):312–7
doi: 10.1093/alcalc/agr017
Müller CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015; 25(8):1167–77
doi: 10.1016/j.euroneuro.2015.04.002
Barrault C, Lison H, Roudot-Thoraval F, et al. One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. Eur J Gastroenterol Hepatol. 2017; 29(10):1155–60
doi: 10.1097/MEG.0000000000000922
Hauser P, Fuller B, Ho SB, et al. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction 2017; 112:1173–83
doi: 10.1111/add.13787
Morley KC, Baillie A, Fraser I, Haber PS. Baclofen in the treatment of alcohol dependence with or without liver disease (BacALD): A multi-site, randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2018; 212:362–9
doi: 10.1192/bjp.2018.13
Mosoni C, Dionisi T, Vassallo GA, et al. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Front Psychiatry. 2018; 9:474
doi: 10.3389/fpsyt.2018.00474
pubmed: 6174362
pmcid: 6174362
Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49(6):2087–107
doi: 10.1002/hep.22853
Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018; 113(2):175–94
doi: 10.1038/ajg.2017.469
pubmed: 6524956
pmcid: 6524956
Agabio R, Sinclair JM, Addolorato G, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry. 2018; 5(12):957–60
doi: 10.1016/S2215-0366(18)30303-1
Edwards S, Kenna, GA, Swift RM, Leggio L. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des. 2011; 17:1323–32
doi: 10.2174/138161211796150765
Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007; 298:1641–51
doi: 10.1001/jama.298.14.1641
Johnson BA, Rosenthal N, Capece JA, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008; 168:1188–99
doi: 10.1001/archinte.168.11.1188
Potts JR, Goubet S, Heneghan MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013; 38(6):584–95
doi: 10.1111/apt.12427
Yamini D, Lee SH, Avanesyan A, Walter M, Runyon B. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol. 2014; 49(4):453–6
doi: 10.1093/alcalc/agu028
Weinrieb RM, Van Horn DH, McLellan AT, et al. Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed. Psychosomatics. 2001; 42(2):110–6
doi: 10.1176/appi.psy.42.2.110
Weinrieb RM, Van Horn DH, McLellan AT, et al. Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates. J Addict Dis. 2001; 20(2):105–19
doi: 10.1300/J069v20n02_09
Anton RF, O’Malley SS, Ciraulo DA, et al; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006; 295(17):2003–17
doi: 10.1001/jama.295.17.2003
Nowinski J, Baker S, Carroll KM. Twelve step facilitation therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Project MATCH monograph series, vol 2. Rockville: NIAAA; 1995
Miller WR, Zweben A, DiClemente CC, et al. Motivational enhancement therapy manual, vol. 2. Rockville: NIAAA 1994
Kadden R, Carroll KM, Donovan D, et al. Cognitive-behavioral coping skills therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence, vol. 3. Rockville: NIAAA 1995
Matching alcoholism treatments to client heterogeneity. Project MATCH post-treatment drinking outcomes. J Stud Alcohol. 1997; 58:7–29
Johnson BA, DiClemente CC, Ait-Daoud N, et al. Brief behavioral compliance enhancement treatment (BBCET) manual. In: Johnson BA, Ruiz P, Galanter M, editors. Handbook of clinical alcoholism treatment. Baltimore: Lippincott Williams & Wilkins; 2003; p. 282–301
Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S; Veterans Affairs Cooperative Study 391 Group. I. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse/physician teams. Alcohol Clin Exp Res. 2003; 27(11):1757–64
doi: 10.1097/01.ALC.0000093744.12232.34
Andersen MM, Aunt S, Jensen NM, et al. Rehabilitation for cirrhotic patients discharged after hepatic encephalopathy improves survival. Dan Med J. 2013; 60(8):A4683
pubmed: 23905568
Drumright LN, Hagan H, Thomas DL, et al. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol. 2011; 55(1):45–52
doi: 10.1016/j.jhep.2010.10.028
Proeschold-Bell RJ, Patkar AA, Naggie S, et al. An integrated alcohol abuse and medical treatment model for patients with hepatitis C. Dig Dis Sci. 2012; 57(4):1083–91
doi: 10.1007/s10620-011-1976-4
Dieperink E, Fuller B, Isenhart C, et al. Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial. Addiction. 2014; 109(11):1869–77
doi: 10.1111/add.12679
Rice JP, Eickhoff J, Agni R, et al. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl. 2013; 19(12):1377–86
doi: 10.1002/lt.23762
Cuadrado A, Fábrega E, Casafont F, Pons-Romero F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2005; 11(4):420–6
doi: 10.1002/lt.20386
Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2007; 13(2):197–205
doi: 10.1002/lt.20934
Masson S, Marrow B, Kendrick S, et al. An ‘alcohol contract’ has no significant effect on return to drinking after liver transplantation for alcoholic liver disease. Transpl Int. 2014; 27(5):475–81
doi: 10.1111/tri.12283
Georgiou G, Webb K, Griggs K, et al. First report of a psychosocial intervention for patients with alcohol-related liver disease undergoing liver transplantation. Liver Transpl. 2003; 9:772–5
doi: 10.1053/jlts.2003.50152
Weinrieb RM, Van Horn DH, Lynch KG, Lucey MR. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl. 2011; 17(5):539–47
doi: 10.1002/lt.22259
Addolorato G, Mirijello A, Leggio L, et al; Gemelli OLT Group. Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res. 2013; 37(9):1601–8
doi: 10.1111/acer.12117
pubmed: 4977094
pmcid: 4977094
Björnsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol. 2005; 40(2):206–16
doi: 10.1080/00365520410009591
Attilia ML, Lattanzi B, Ledda R, et al. The multidisciplinary support in preventing alcohol relapse after liver transplantation: A single-center experience. Clin Transplant. 2018; 32(5):e13243
doi: 10.1111/ctr.13243
Dieperink E, Ho S, Heit S, et al. Significant Reductions in Drinking Following Brief Alcohol Treatment Provided in a Hepatitis C Clinic. Psychosomatics. 2010; 51:149–56
doi: 10.1016/S0033-3182(10)70675-7
Heyes CM, Schofield T, Gribble R, Day CA, Haber PS. Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant. Patients: A Qualitative Study. Transplant Direct. 2016; 2(10):e104
pubmed: 27795986
Sobell LC, Maisto SA, Sobell MB, et al. Reliability of alcohol abusers’ self-reports of drinking behavior. Behav Res Ther. 1979; 17:157–60
doi: 10.1016/0005-7967(79)90025-1
Yang JD1, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448–58
doi: 10.1038/nrgastro.2010.100
pubmed: 3926946
pmcid: 3926946
El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000; 160:3227–323
doi: 10.1001/archinte.160.21.3227
Ge PS & Runyon BA. Treatment of Patients with Cirrhosis. N Engl J Med. 2016; 375(8):767–77
doi: 10.1056/NEJMra1504367
Mirijello A, Tarli C, Vassallo GA, et al. Alcoholic cardiomyopathy: What is known and what is not known. Eur J Intern Med. 2017; 43:1–5.
doi: 10.1016/j.ejim.2017.06.014
Vassallo G, Mirijello A, Antonelli M, Ferrulli A, Addolorato G. Liver transplantation for alcoholic liver disease. J Alcohol Drug Depend. 2013; 2:143.
doi: 10.4172/2329-6488.1000143
Addolorato G, Bataller R, Burra P, et al. Liver Transplantation for Alcoholic Liver Disease. Transplantation. 2016; 100(5):981–7
doi: 10.1097/TP.0000000000001156
Vassallo GA, Tarli C, Rando MM, et al. Liver Transplantation in Patients with Alcoholic Liver Disease: A Retrospective Study. Alcohol Alcohol. 2018; 53(2):151–6.
doi: 10.1093/alcalc/agx097